Cancer Group Presses For Standardized Expanded Access Programs
This article was originally published in The Pink Sheet Daily
Executive Summary
A citizen petition by the National Coalition for Cancer Survivorship could inform future FDA guidance on the topic.
You may also be interested in...
India Highlights "Public Interest" To Reign In Prices For Non-Scheduled Drugs
Dr. Reddy's, GSK, Ranbaxy and UCB among manufacturers that could see prices reduced under government order that reflects issues raised in Gleevec patent dispute.
Indian Health Minister Asks Novartis to Stand Down On Gleevec Patent Fight
Indian regulators threaten compulsory licensing of the oncologic, but Novartis says it has no plans to end its bid for patent protection.
Lost In Bureaucracy? Novartis Gleevec IP Case Held Up By Indian Legal System
Patent case for new form of imatinib will now be reviewed by newly formed Intellectual Property Appellate Board.